Austin Chemical Company, Syncom and ChemConnection establish joint venture SynConnection LLC

SYNCONNECTION LOGO RGB

Advancing health through connecting science 

Austin Chemical Company Inc, a pharmaceutical procurement and logistics service provider announced today the joint venture with Syncom BV, a pharmaceutical contract synthesis company, and ChemConnection BV, a GMP licensed contact manufacturing company.

The development of novel active pharmaceutical ingredients (NCEs, APIs) demands a broad range of specialized technologies that should be combined to enable the shortest development time to clinical evaluation. The SynConnection companies, each building upon decades of pharmaceutical development history, join forces providing optimal chemical contract development services for small- and mid-sized pharma and biotech companies. SynConnection offers specialized IND/IMPD enabling technologies including chiral resolution and process development, GMP manufacturing of highly potent materials, complex purifications, analytical development and validation, nanomedicines manufacturing, as well as global logistics and procurement.

Sam Ponticelli, CEO of Austin Chemical Company, commented: “We are very pleased with this exciting cooperation. This joint venture officially connects decades of pharmaceutical development history”

Ton Vries, CEO of Syncom, commented: “For Syncom this joint venture is a tremendous step forward. Syncom has been working with leading pharmaceutical and biotech companies around the world and has established a solid name in the preclinical pharmaceutical contract synthesis market. Joining forces with Austin Chemical and ChemConnection now adds specialized GMP manufacturing services and knowledge to our portfolio. The SynConnection cooperation will give us the opportunity to further assist our customers with developing their pipeline. It also enforces the excellent longstanding relationship with the ChemConnection team.”

Gerjan Kemperman, CEO of ChemConnection, commented: “Our competences build upon the legacy history from Organon Biosciences. The ChemConnection team has developed a multitude of NCEs from research to clinical evaluation, and has established an enormous knowledge base. We are dedicated to advancing health by offering our services to small-and mid-sized pharma companies. The cooperation within SynConnection has expanded our company to a globally operating enterprise.”